Last reviewed · How we verify
MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]
MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses.
MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses. Used for Prevention of Ebola virus disease, Prevention of Marburg virus disease.
At a glance
| Generic name | MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] |
|---|---|
| Sponsor | Janssen Vaccines & Prevention B.V. |
| Drug class | Recombinant viral vector vaccine |
| Target | Filovirus glycoproteins (Ebola virus GP, Marburg virus GP) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This vaccine uses a non-replicating viral vector (MVA) engineered to express surface glycoproteins from Ebola and Marburg viruses. It stimulates both cellular and humoral immune responses, training T cells and B cells to recognize filoviral antigens before natural infection occurs. MVA-BN-Filo is typically used as a prime in heterologous prime-boost vaccination regimens to establish broad immunity against filovirus infection.
Approved indications
- Prevention of Ebola virus disease
- Prevention of Marburg virus disease
Common side effects
- Injection site pain or erythema
- Myalgia
- Fatigue
- Headache
- Fever
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: